Internal Medicine, Endocrinology, Diabetes, & Metabolism · Providence, RI
NPI
1598863599
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
100 Highland Ave, 203
Providence, RI, 02906
Phone (401) 351-7100
Groups this clinician bills Medicare through
Medicare paid, 2024
$228K
10,382 services
Medicare patients, 2024
706
Average age 75
Drug cost, 2024
$5.5M
17,806 prescriptions
Company payments, 2025
$45K
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Robert J Dobrzynski Jr. was code 84443 (clinical chemistry), 1,180 times for 634 patients. In total Robert J Dobrzynski Jr. billed 10,382 services in 36 codes, and Medicare paid $228K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-12-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 84443 Clinical Chemistry | Office | 1,180 | 634 | $16.42 | $19K |
| 83036 Blood Count | Office | 1,109 | 545 | $9.48 | $11K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,097 | 531 | $12.59 | $14K |
| 99214 Office E&M - Established | Office | 1,093 | 530 | $91.77 | $100K |
| 36415 Venipuncture Blood Collection | Office | 1,062 | 605 | $8.65 | $9,186 |
| 80053 Clinical Chemistry | Office | 956 | 472 | $10.30 | $9,849 |
| 84439 Clinical Chemistry | Office | 867 | 511 | $8.81 | $7,641 |
| 84481 Clinical Chemistry | Office | 593 | 341 | $16.55 | $9,813 |
| 83721 Clinical Chemistry | Office | 355 | 244 | $10.22 | $3,630 |
| 80061 Clinical Chemistry | Office | 355 | 244 | $13.06 | $4,635 |
| 82043 Clinical Chemistry | Office | 340 | 241 | $5.62 | $1,910 |
| 82570 Clinical Chemistry | Office | 339 | 240 | $5.04 | $1,709 |
| 99213 Office E&M - Established | Office | 239 | 195 | $59.33 | $14K |
| 95251 Test - Miscellaneous | Office | 218 | 116 | $26.05 | $5,680 |
| 80048 Clinical Chemistry | Office | 183 | 148 | $8.29 | $1,517 |
By year: 2022 $213K for 9,691 services; 2023 $202K for 8,866 services; 2024 $228K for 10,382 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 84443 Clinical Chemistry | 1,180 | 634 | $16.42 | $19K |
| 83036 Blood Count | 1,109 | 545 | $9.48 | $11K |
| 36415 Venipuncture Blood Collection | 1,062 | 605 | $8.65 | $9,186 |
| 80053 Clinical Chemistry | 956 | 472 | $10.30 | $9,849 |
| 84439 Clinical Chemistry | 867 | 511 | $8.81 | $7,641 |
| 84481 Clinical Chemistry | 593 | 341 | $16.55 | $9,813 |
| 83721 Clinical Chemistry | 355 | 244 | $10.22 | $3,630 |
| 80061 Clinical Chemistry | 355 | 244 | $13.06 | $4,635 |
| 82043 Clinical Chemistry | 340 | 241 | $5.62 | $1,910 |
| 82570 Clinical Chemistry | 339 | 240 | $5.04 | $1,709 |
Medicare prescription drug claims, 2024
In 2024, the drug Robert J Dobrzynski Jr. prescribed most often to Medicare patients was Levothyroxine Sodium, with 2,376 prescriptions and refills. In total Robert J Dobrzynski Jr. wrote 17,806 Medicare prescriptions that cost $5.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 2,376 | 5,720 | 523 | $28K |
| Ozempic Semaglutide | 1,203 | 1,419 | 183 | $1.3M |
| Glimepiride Generic | 1,122 | 2,904 | 287 | $16K |
| Metformin Hcl Generic | 938 | 2,473 | 243 | $9,435 |
| Jardiance Empagliflozin | 681 | 1,023 | 124 | $591K |
| Farxiga Dapagliflozin Propanediol | 671 | 937 | 101 | $513K |
| Atorvastatin Calcium Generic | 658 | 1,673 | 170 | $6,926 |
| Synthroid Levothyroxine Sodium | 516 | 1,196 | 113 | $42K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 503 | 953 | 163 | $41K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 444 | 912 | 136 | $77K |
| Losartan Potassium Generic | 367 | 941 | 94 | $4,024 |
| Toujeo Solostar Insulin Glargine,hum.Rec.Anlog | 357 | 604 | 78 | $253K |
| Humalog Kwikpen U-100 Insulin Lispro | 355 | 610 | 94 | $100K |
| Trulicity Dulaglutide | 275 | 312 | 48 | $290K |
| Humalog Insulin Lispro | 255 | 376 | 54 | $53K |
Brand drugs: 7,879 claims; generic drugs: 8,781 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Robert J Dobrzynski Jr. $45K ($45K in general payments such as food, travel and fees) from 6 companies. The largest payer was Novo Nordisk Inc with $30K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.